Krystal Biotech (KRYS) AI Stock Analysis

• Market Cap: $6.34B
• Dividend Yield: N/A
• Average Volume (3M): 300.68K
• Price to Earnings (P/E): 32.8
• Beta (1Y): 0.78
• Revenue Growth: 54.51%
• EPS Growth: 275.94%
• Country: US
• Employees: 275
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.66
• Shares Outstanding: 28,997,519
• 10 Day Avg. Volume: 233,717
• 30 Day Avg. Volume: 300,679
• PEG Ratio: 0.07
• Price to Book (P/B): 4.73
• Price to Sales (P/S): 15.42
• P/FCF Ratio: 37.58
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 12.18
• Enterprise Value/Gross Profit: 12.97
• Enterprise Value/Ebitda: 26.55
• 1Y Price Target: $221.00
• Price Target Upside: 1.05% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): 6.29
• Revenue Forecast (FY): $387.75M

• Rating: 80 Outperform
• Price Target: $251.00 ▲(14.77% Upside)

Krystal Biotech's strong financial performance and positive earnings call are the most significant factors driving the stock score. The company's robust revenue growth, profitability, and strategic international expansion are key strengths. Technical analysis indicates strong bullish momentum, although the stock appears overbought. Valuation concerns due to a high P/E ratio and lack of dividend yield slightly offset these positives.

Positive Factors

Strong Financial Position

A robust cash position enhances Krystal Biotech's ability to invest in R&D, support commercial activities, and withstand market fluctuations, ensuring long-term growth potential.

FDA Label Update for VYJUVEK

The FDA label update broadens the market for VYJUVEK, potentially increasing sales and improving the company's competitive position in treating DEB.

Platform Therapy Designation

This designation could expedite approval processes for future therapies, enhancing Krystal Biotech's pipeline potential and long-term growth prospects.

Negative Factors

Gross Margin Challenges Outside U.S.

Inability to optimize manufacturing processes internationally may lead to lower margins, impacting profitability and competitive edge in global markets.

Long Path to Full Market Penetration

Achieving full market penetration is crucial for maximizing revenue potential. Delays could slow growth and limit the company's market leadership.

Temporary U.S. Revenue Decline

While temporary, a decline in U.S. revenue highlights potential volatility in domestic sales, which could affect short-term financial stability and investor confidence.

Krystal Biotech Business Overview & Revenue Model

Company Description

Krystal Biotech, Inc. is a biotechnology company focused on developing transformative gene therapies for patients with debilitating skin diseases. The company specializes in its proprietary Skin TARGET technology platform, which facilitates the delivery of therapeutic genes to the skin. Krystal Biotech's core products include therapies for conditions such as dystrophic epidermolysis bullosa and other dermatological disorders, aimed at addressing significant unmet medical needs.

How the Company Makes Money

Krystal Biotech generates revenue primarily through the commercialization of its gene therapy products. This includes product sales from approved therapies, which can be substantial given the high demand for effective treatments in rare diseases. Additionally, the company may enter into strategic partnerships with pharmaceutical companies or research institutions to develop and market its products, which can provide upfront payments, milestone payments, and royalties based on future sales. The ongoing development of new therapies and potential expansions into additional markets also contribute to their revenue streams.

Krystal Biotech Financial Statement Overview

Summary

Krystal Biotech demonstrates strong financial health with impressive revenue growth and profitability metrics. The balance sheet is robust with minimal leverage, enhancing financial stability. While cash flow metrics show some decline in free cash flow growth, the company maintains strong cash generation capabilities. Overall, the financial statements reflect a company on a positive growth trajectory with solid operational and financial management.

Income Statement

Krystal Biotech has shown impressive revenue growth with a 3.89% increase in TTM, following a 4.73% growth in the previous year. The company maintains strong profitability with a TTM gross profit margin of 68.78% and a net profit margin of 53.30%. The EBIT and EBITDA margins are also robust at 33.32% and 45.67%, respectively, indicating efficient operational management. However, the company has transitioned from negative EBIT in earlier years, reflecting a significant turnaround in profitability.

Balance Sheet

The balance sheet is strong with a very low debt-to-equity ratio of 0.0015 in TTM, indicating minimal leverage and financial risk. The return on equity (ROE) has improved significantly to 19.36% in TTM, showcasing effective use of equity to generate profits. The equity ratio stands at a healthy level, reflecting a solid capital structure with a high proportion of equity financing.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth by 10.71% in TTM, which could be a concern. However, the operating cash flow to net income ratio is strong at 1.93, indicating good cash generation relative to net income. The free cash flow to net income ratio is also healthy at 0.94, suggesting that the company is effectively converting its earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	373.16M	290.51M	50.70M	0.00	0.00	0.00
Gross Profit	350.36M	270.45M	47.60M	0.00	0.00	-1.85M
EBITDA	171.17M	109.91M	-91.32M	-116.81M	-66.23M	-30.32M
Net Income	198.91M	89.16M	10.93M	-139.97M	-69.57M	-32.17M
Balance Sheet
Total Assets	1.24B	1.06B	818.36M	558.45M	626.29M	310.84M
Cash, Cash Equivalents and Short-Term Investments	731.07M	597.52M	532.18M	379.17M	438.10M	271.26M
Total Debt	9.51M	7.26M	8.09M	8.93M	8.02M	11.55M
Total Liabilities	102.22M	109.46M	39.71M	36.22M	32.72M	18.76M
Stockholders Equity	1.14B	946.38M	778.64M	522.23M	593.58M	292.08M
Cash Flow
Free Cash Flow	165.59M	119.18M	-100.60M	-153.55M	-116.27M	-40.93M
Operating Cash Flow	176.20M	123.42M	-88.80M	-100.57M	-47.94M	-26.08M
Investing Cash Flow	-153.36M	-163.44M	82.64M	-114.08M	-226.77M	-11.18M
Financing Cash Flow	-4.53M	27.01M	202.75M	35.35M	347.69M	118.02M

Krystal Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 218.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRYS, the sentiment is Positive. The current price of 218.7 is above the 20-day moving average (MA) of 204.11, above the 50-day MA of 190.03, and above the 200-day MA of 163.00, indicating a bullish trend. The MACD of 7.52 indicates Negative momentum. The RSI at 74.32 is Negative, neither overbought nor oversold. The STOCH value of 83.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRYS.

Krystal Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	80 Outperform	$6.34B	32.80	19.66%	―	54.51%	275.94%
ALKS	74 Outperform	$4.91B	14.70	22.35%	―	1.08%	3.40%
PTCT	73 Outperform	$6.92B	10.08	―	―	97.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLTX	41 Neutral	$984.96M	―	-54.17%	―	―	-157.74%
ACLX	41 Neutral	$4.24B	―	-47.18%	―	-76.96%	-425.41%
CRSP	40 Underperform	$5.08B	―	-25.33%	―	-81.10%	-99.21%

Krystal Biotech Corporate Events

Krystal Biotech’s Earnings Call Highlights Growth and Challenges

Krystal Biotech’s recent earnings call painted a picture of robust financial health and strategic international growth. The sentiment was largely positive, with significant revenue growth and successful international expansion efforts. However, the company acknowledged ongoing challenges in achieving full market penetration and optimizing global margins.

Krystal Biotech Reports Strong Q3 2025 Performance

Krystal Biotech, Inc. is a global biotechnology company focused on developing genetic medicines for serious and rare diseases, with a strong emphasis on dermatology and respiratory conditions.

Krystal Biotech’s Promising Lung Cancer Study: A Potential Game-Changer?

Krystal Biotech, Inc. is conducting a clinical study titled ‘KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs.’ The study aims to assess the safety, tolerability, and preliminary efficacy of KB707, a novel therapeutic designed to stimulate an anti-tumor immune response in the lungs of patients with advanced solid tumors.

Krystal Biotech’s KB407 Study: A Promising Step for Cystic Fibrosis Treatment

Krystal Biotech, Inc. is conducting a Phase 1 clinical study titled KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis. The study aims to evaluate the safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis, a significant step in addressing this chronic genetic condition.

Krystal Biotech’s Innovative Approach to Treating Alpha-1 Antitrypsin Deficiency: A Clinical Update

Krystal Biotech, Inc. (KRYS) is conducting a Phase 1 study titled ‘A Phase 1 Study of Inhaled KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency.’ The study aims to evaluate the safety and pharmacodynamics of KB408, a novel treatment for alpha-1 antitrypsin deficiency (AATD), a genetic condition affecting the lungs. The significance of this study lies in its potential to offer a new therapeutic option for individuals with AATD.

Krystal Biotech Advances DEB Research with New Observational Study

Krystal Biotech, Inc. is conducting a study titled ‘A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB).’ The primary objective is to observe and document the natural progression of corneal abrasions in DEB patients, a condition that can severely impact quality of life. Understanding these patterns is crucial for developing future treatments.

Krystal Biotech’s Promising Study on KB803 for DEB: A Potential Game Changer?

Krystal Biotech, Inc. is conducting a clinical study titled ‘A Double-Blind Crossover of KB803 and Matched Placebo, for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa.’ The study aims to evaluate the safety and efficacy of KB803, a treatment designed to address recurrent corneal abrasions in patients with dystrophic epidermolysis bullosa (DEB). This condition is significant due to its impact on quality of life, making effective treatments crucial.

Krystal Biotech’s Promising Study on KB801 for Neurotrophic Keratitis: Market Implications

Krystal Biotech, Inc. is conducting a clinical study titled ‘A Phase 1/2, Multicenter, Double-Masked, Placebo-Controlled Study of KB801 in Subjects With Stage 2 or 3 Neurotrophic Keratitis.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of KB801, a novel treatment for neurotrophic keratitis, a degenerative eye condition. This study is significant as it targets a condition with limited treatment options, potentially offering a new therapeutic pathway.

Krystal Biotech’s KB707 Study: A New Hope for Advanced Cancer Treatment

Krystal Biotech, Inc. is conducting a Phase 1/2 clinical study titled ‘A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies.’ The study aims to assess the safety, tolerability, and preliminary efficacy of KB707, a genetically modified herpes simplex type 1 virus, in treating patients with advanced solid tumors, including melanoma. This research is significant as it explores new treatment avenues for patients who have limited options due to the progression or intolerance of standard therapies.

Krystal Biotech Launches VYJUVEK® in Japan

On October 22, 2025, Krystal Biotech‘s subsidiary in Japan launched VYJUVEK® for treating dystrophic epidermolysis bullosa, following its inclusion in Japan’s National Health Insurance Drug Price List. This marks a significant step in Krystal Biotech’s expansion into the Japanese market, potentially enhancing its industry positioning and offering new treatment options for patients.

The most recent analyst rating on (KRYS) stock is a Buy with a $255.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.